173 related articles for article (PubMed ID: 10520715)
1. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA
J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715
[TBL] [Abstract][Full Text] [Related]
2. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.
Sgouros G; Ballangrud AM; Jurcic JG; McDevitt MR; Humm JL; Erdi YE; Mehta BM; Finn RD; Larson SM; Scheinberg DA
J Nucl Med; 1999 Nov; 40(11):1935-46. PubMed ID: 10565792
[TBL] [Abstract][Full Text] [Related]
4. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
[TBL] [Abstract][Full Text] [Related]
5. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
[TBL] [Abstract][Full Text] [Related]
6. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
[TBL] [Abstract][Full Text] [Related]
7. In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes.
Abbas Rizvi SM; Henniker AJ; Goozee G; Allen BJ
Leuk Res; 2002 Jan; 26(1):37-43. PubMed ID: 11734302
[TBL] [Abstract][Full Text] [Related]
8. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
Ma D; McDevitt MR; Finn RD; Scheinberg DA
Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
11. An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.
McDevitt MR; Finn RD; Sgouros G; Ma D; Scheinberg DA
Appl Radiat Isot; 1999 May; 50(5):895-904. PubMed ID: 10214708
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
13. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals.
Ma D; McDevitt MR; Finn RD; Scheinberg DA
Appl Radiat Isot; 2001 Oct; 55(4):463-70. PubMed ID: 11545498
[TBL] [Abstract][Full Text] [Related]
14. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
Xu Y; Xu Q; Rosenblum MG; Scheinberg DA
Leukemia; 1996 Feb; 10(2):321-6. PubMed ID: 8637241
[TBL] [Abstract][Full Text] [Related]
15. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
Zalutsky MR; Zhao XG; Alston KL; Bigner D
J Nucl Med; 2001 Oct; 42(10):1508-15. PubMed ID: 11585865
[TBL] [Abstract][Full Text] [Related]
16. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
[TBL] [Abstract][Full Text] [Related]
17. Efforts to control the errant products of a targeted in vivo generator.
Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
[TBL] [Abstract][Full Text] [Related]
18. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
Caron PC; Dumont L; Scheinberg DA
Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]